Top Analyst Upgrades and Downgrades: Arena Pharma, Autodesk, Coca-Cola, GE, Marvell, Monster Beverages, Nabors, Procter & Gamble and More

Investing

December 13, 2018 9:15 am

Last Updated: January 11, 2020 1:46 pm

Procter & Gamble Co. (NYSE: PG) was raised to Buy from Neutral at Merrill Lynch. The 52-week trading range for the consumer good giant is $70.73 to $94.86. The consensus price target is $89.47. The shares closed Wednesday at $94.03.

Coca-Cola Co. NYSE: KO) was resumed in coverage with a Neutral rating at UBS, which has a $51 price target. The consensus target for the beverage giant is $51.72. The stock closed Wednesday at $49.22.

Other key analysts upgrades and downgrades were seen in the following:

Cognex Corp. (NASDAQ: CGNX) saw its target price raised to $47 from $45 at Needham after the firm met with analysts yesterday. The firm kept its Buy rating on the stock, which has traded between $36.16 and $70 over the past year, and the consensus price objective is $49.38. The shares ended trading on Wednesday at $41.85.

DocuSign Inc. (NASDAQ: DOCU) was started with a Neutral rating and a $45 price objective at Goldman Sachs. The consensus price target is $59. The stock closed trading on Wednesday at $42.40, and despite the tepid initiation, shares were higher in premarket trading.

Five Below Inc. (NASDAQ: FIVE) was raised to Buy from Neutral at Goldman Sachs. The stock has traded between $60 and $136.16 over the past year. The consensus price target is $127.65. The shares ended trading on Wednesday at $101.40 but were up on the news in the premarket.

GCP Applied Technologies Inc. (NYSE: GCP) was resumed in coverage with a Neutral rating at C.L. King. The 52-week trading range is $23.85 to $34.79. The consensus price target is $29.50. The stock closed Wednesday at $25.43.

24/7 Wall St.
10 ETFs to Help Avoid a Stock Market Crash and Maybe Even Profit From It!

Molson Coors Brewing Co. (NYSE: TAP) was started with a Buy rating at UBS, which has an $80 price target on the beer giant. That compares with a consensus price target of $72.88. The stock ended trading on Wednesday at $63.07.

Neurocrine Biosciences Inc. (NASDAQ: NBIX) was started with a Buy rating at Goldman Sachs, which has a $103 price objective. That compares with a consensus target of $113.93. The stock ended up on Wednesday at $73.83, down a whopping 14% after posting some disappointing clinical data.

Sabre Corp. (NASDAQ: SABR) was downgraded to Hold from Buy at Deutsche Bank. Shares have traded in a 52-week range of $17.91 to $26.78, and the consensus price objective is $28.00. The stock ended trading on Wednesday at $24.99.

Medicines Co. Inc. (NASDAQ: MDCO) was started with a Neutral rating and a $25 price target at Goldman Sachs. The consensus target is $48.60, and shares closed Wednesday at $28.21.

In case you missed it, Wednesday’s top analyst upgrades and downgrades included American Tower, American Waterworks, Bank of America, eBay, FedEx, Lululemon Athletica, Morgan Stanley, Vale, Verizon and more.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.